EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liposomal Iron Oxide Nanoparticles Loaded with Doxorubicin for Combined Chemo-Photothermal Cancer Therapy

Taehoon Park, Reeju Amatya, Kyoung Ah Min, Meong Cheol Shin iD

Pharmaceutics · 15.01.2023 · 15 (1) · 292

DOI: 10.3390/pharmaceutics15010292 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 15.01.2023. Verfasst von Taehoon Park und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju Daero, Jinju 52828, Gyeongnam, Repub…. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Education, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iron oxide nanoparticle (IONP) possesses unique advantages over other nanoparticles in the use of cancer imaging and therapy. Specifically, it has drawn great attention in the emerging research field of photothermal cancer therapy. Herein, we developed doxorubicin (DOX)-loaded liposomal IONP (Lipo-IONP/DOX) and evaluated in vitro and in vivo their applicability for combined chemo-photothermal cancer therapy. The Lipo-IONP was synthesized by the thin-film evaporation method. The prepared Lipo-IONP was observed as about a 240 nm-sized agglomerate of globular-shaped nanoparticles. The TEM and FT-IR data evidenced the successful formation of liposomal IONP. The superparamagnetic property of the Lipo-IONP was confirmed by the SQUID analysis. The DSC data showed a transition temperature of about 47–48 °C for the mixed lipids composing the Lipo IONP, and the DOX release studies revealed the feasibility of induced burst release of DOX by laser irradiation. The Lipo-IONP/DOX possessed a plasma half-life of 42 min, which could ensure sufficient circulation time for magnetic tumor targeting. The in vivo magnetic targeting enabled a significant increase (6.3-fold) in the tumor accumulation of Lipo-IONP/DOX, leading to greater photothermal effects. Finally, the preliminary efficacy study evidenced the applicability as well as the safety of the Lipo-IONP/DOX for use in combined chemo-photothermal cancer therapy. Overall, the study results demonstrated that the Lipo-IONP/DOX might serve as an effective and safe agent for combined chemo-photothermal cancer therapy.

Schlagwörter

Stichwörter der Autor:innen

cancerdoxorubiciniron oxide nanoparticleliposomemagnetic targetingphotothermal therapy

Autor:innen und Institutionen

  • College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju Daero, Jinju 52828, Gyeongnam, Republic of Korea.
  • College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, 197 Injero, Gimhae 50834, Gyeongnam, Republic of Korea.

ORCID-Profile: Meong Cheol Shin

Förderung

  • National Research Foundation of Korea
  • Ministry of Education, Science and Technology

Zitieren

APA

Park, T., Amatya, R., Min, K. A., & Shin, M. C. (2023). Liposomal Iron Oxide Nanoparticles Loaded with Doxorubicin for Combined Chemo-Photothermal Cancer Therapy. Pharmaceutics, 15(1), 292. https://doi.org/10.3390/pharmaceutics15010292

Vancouver

Park T, Amatya R, Min KA, Shin MC. Liposomal Iron Oxide Nanoparticles Loaded with Doxorubicin for Combined Chemo-Photothermal Cancer Therapy. Pharmaceutics. 2023;15(1):292. doi:10.3390/pharmaceutics15010292

BibTeX
@article{Park2023,
  author = {Park, Taehoon and Amatya, Reeju and Min, Kyoung Ah and Shin, Meong Cheol},
  title = {Liposomal Iron Oxide Nanoparticles Loaded with Doxorubicin for Combined Chemo-Photothermal Cancer Therapy},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {1},
  pages = {292},
  doi = {10.3390/pharmaceutics15010292}
}
Kostenlos starten →